Skip to main content
OpenTrials
Completed

NCT Number: NCT04529174

Oral Nutritional Supplement Effect on HDL Function

Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hypertension Institute

Nashville, Tennessee, 37205, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and non-pregnant female patients or female patients of childbearing age on contraception age 18-80years.
  • Total HDL level 38mg/dL or lower in men and HDL 45 mg/dL or lower in women and a low HDL-P defined as less than 7000 by Spectracell LPP Plus.
  • CHL HDL Fx score equal to or greater than 0.9.
  • Patients will remain on their present diet, exercise program, medications (except for those who alter serum lipids) sleeping habits, alcohol intake, caffeine intake, smoking amount and emotional status as best as possible related to stress and anxiety and maintain body weight at baseline visit as best as possible to avoid confounding variables.
  • No other lipid lowering supplement can be taken during the study.
  • All lipid lowering supplements must have been discontinued at least 30 days prior t o study entry.

Exclusion criteria

  • Pregnant females
  • Females of childbearing age not on an accepted contraception control method
  • Previous myocardial infarction within 5 years
  • Unstable angina
  • Previous stroke or TIA within 5 years
  • Uncompensated congestive heart failure
  • Previous PCTA or stent within 5 years
  • Previous CABG within 5 years
  • Patients on statins, fibrates, or other lipid lowering medications or any supplement known to affect serum lipids.
  • Known or previous cancer within 5 years
  • Type 1 diabetes mellitus
  • Kidney disease as defined by serum creatinine over 2.5 mg/dL

Treatment and study plan

CardioLux™HDL

Dietary Supplement

Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).

Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.

Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.

Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)

Placebo

Dietary Supplement

Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).

Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.

Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.

Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)

Primary outcomes

  1. HDL-FX test HDL-FX test

    Time frame: Change from Baseline to End of Study (week 12)

    Reverse Cholesterol Transport (RCT)(CEC) with Cleveland Heart Lab (CHL)

  2. HDL mapping

    Time frame: Change from Baselineto End of study (week 12)

    HDL mapping with Boston Heart Lab (BHL)

Secondary outcomes

  1. Myloperoxidase (MPO)

    Time frame: Change from Baseline to End of Study (week 12)

    measured with Quest Lab test

  2. LP-PLA-2 test

    Time frame: Change from Baseline to End of Study (week 12)

    Measured with Quest Lab test

  3. Dietary Intake

    Time frame: Change from Baseline to End of Study (week 12)

    24 hour recall

Other outcomes

  1. Weight

    Time frame: Change from Baseline to End of Study (week 12)

    measured in pounds (Lbs)

  2. Body Mass Index

    Time frame: Change from Baseline to End of Study (week 12)

    measured in kg/m2

  3. Waist Circumference

    Time frame: Change from Baseline to End of Study (week 12)

    measured in cm

  4. Blood pressure (systolic/diastolic)

    Time frame: Change from Baseline to End of Study (week 12)

    measured in mm Hg

Sponsors and collaborators

Lead sponsor

Metagenics, Inc.

Industry

Registry information

Official study title

Evaluation of an Oral Nutritional Supplement for Effect on Total High-Density Lipoprotein (HDL) Cholesterol, HDL Functionality, Particle Size and Number

Important dates

Study start
2020
Primary completion
2021
Study completion
2023
First posted
Aug 27, 2020
Registry last updated
Mar 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.